Tristan Manalac is a contributing writer at BioSpace. With over eight years of experience, he specializes in medicine, healthcare, and alternative medicine, drawing on his formal training in molecular biology to inform his writing. Tristan's work often explores topics such as the FDA, Coronavirus, and legal affairs within the medical field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Tristan Manalac's coverage predominantly focuses on the healthcare and pharmaceutical industry, particularly FDA approvals, drug development, and related market movements. His reliance on press releases and data citations suggests a preference for fact-based reporting.
Given his focus on specific companies and regulatory developments in the pharmaceutical industry, Tristan is likely to be responsive to pitches from experts with direct knowledge of relevant drugs, therapies or regulatory processes. Additionally, he may be interested in insights into market trends impacting drug pricing or innovative approaches in drug development.
While geographic focus isn't specified, considering that pharma news often has global implications due to multinational companies involved in research and distribution of drugs worldwide would also be important when reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Tristan Manalac
Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage failures.
By: Tristan Manalac
The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help shore up sales of their Eylea franchise amid biosimilar encroachment.
By: Tristan, Manalac
Tenaya's share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the Phase Ib/II trial than in preclinical models, according to William Blair analysts.
The letters come amid the Outsourcing Facilities Association’s ongoing lawsuit against the FDA over the regulator’s decision to end the shortage for tirzepatide.
The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk and Roche.
By: Tristan, Manalac
The approval concludes what has been a difficult regulatory path for Ryoncil, which suffered FDA rejections in 2020 and 2023.
By: Tristan, Manalac
According to the World Health Organization, GLP-1 receptor agonists are currently being used in a highly medicalized manner. Healthcare systems need to enact more holistic solutions, focusing on health promotion, disease prevention and policy interventions.
Vertex Pharmaceuticals' investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their concerns as the company's share price fell 13% in premarket trading.
Investors appeared disappointed by CagriSema's Phase III readout, which showed weight loss that fell short of Novo Nordisk's prior projections for the therapy. Meanwhile, Eli Lilly's stock rose on the news.
Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the cardiovascular and sleep apnea markets, and show potential in several other indications, including cancer, addiction and neurodegenerative disease.
(833) 317-6278 
